Loading...
XJPX
4888
Market cap56mUSD
Jul 10, Last price  
324.00JPY
1D
7.28%
1Q
-55.00%
IPO
-55.06%
Name

Stella Pharma Corp

Chart & Performance

D1W1MN
XJPX:4888 chart
P/E
P/S
30.58
EPS
Div Yield, %
Shrs. gr., 5y
4.33%
Rev. gr., 5y
9.44%
Revenues
323m
-66.35%
00205,968,000100,096,000229,067,000269,491,000961,058,000323,389,000
Net income
-781m
L+454.59%
-859,007,000-962,238,000-659,244,000-767,719,000-778,824,000-763,749,000-140,811,000-780,917,000
CFO
-335m
L
-771,343,000-913,583,000-772,811,000-1,081,129,000-827,669,000-876,837,000140,408,000-334,514,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.
IPO date
Apr 22, 2021
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT